Clinical trial
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
NCT00036543 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00036543 |
|---|---|
| Title | A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Atrasentan |
| Enrollment | 1,000 |
| Start date | May 1, 2001 |
| First posted | May 13, 2002 |
| Last update posted | Aug 15, 2006 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: